Yahoo · Oct 9, 2026
ADC Therapeutics Cuts Debt, Extends Runway Ahead of Key Drug Data, RBC Says
ADC Therapeutics (ADCT) cut debt and extended its cash runway, reducing pressure on its balance shee
AD
NYSE · ADCT
ADC Therapeutics S.A.
Healthcare · Biotechnology
$1.44
Up+$0.08 (+5.56%)
Updated Oct 20, 2026, 8:28 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 507.9M
- P/E ratio
- -3.35
- Dividend yield
- 0.00%
- 52-week range
- $0.78 – $4.98
- Volume
- 575.62K
- Avg. volume
- 1.16M
Price performance · ADCT
ADCT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 19, 2026
ADCT closed at $1.44 after 21 trading sessions, up 28.57% for the selected period.
- Last close
- $1.44
- Period change
- +28.57%
- Period low
- $1.08
- Period high
- $1.86
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 19, 2026 | $1.40 | $1.49 | $1.39 | $1.44 | 575.62K |
| Oct 16, 2026 | $1.49 | $1.51 | $1.40 | $1.40 | 799.53K |
| Oct 15, 2026 | $1.47 | $1.565 | $1.46 | $1.49 | 1.33M |
| Oct 14, 2026 | $1.67 | $1.725 | $1.40 | $1.45 | 1.74M |
| Oct 13, 2026 | $1.86 | $1.86 | $1.625 | $1.70 | 3.33M |
| Oct 12, 2026 | $1.70 | $1.87 | $1.64 | $1.86 | 1.59M |
| Oct 9, 2026 | $1.58 | $1.83 | $1.56 | $1.73 | 3.14M |
| Oct 8, 2026 | $1.41 | $1.63 | $1.32 | $1.59 | 5.55M |
| Oct 7, 2026 | $1.25 | $1.44 | $1.235 | $1.42 | 1.75M |
| Oct 6, 2026 | $1.25 | $1.27 | $1.20 | $1.27 | 1.35M |
| Oct 5, 2026 | $1.12 | $1.26 | $1.11 | $1.23 | 1.75M |
| Oct 2, 2026 | $1.10 | $1.14 | $1.06 | $1.13 | 1.32M |
| Oct 1, 2026 | $1.20 | $1.201 | $1.07 | $1.08 | 862.27K |
| Sep 30, 2026 | $1.23 | $1.285 | $1.20 | $1.22 | 1.11M |
| Sep 29, 2026 | $1.27 | $1.29 | $1.20 | $1.23 | 781.02K |
| Sep 28, 2026 | $1.24 | $1.27 | $1.20 | $1.26 | 835.12K |
| Sep 25, 2026 | $1.26 | $1.285 | $1.21 | $1.27 | 1.08M |
| Sep 24, 2026 | $1.305 | $1.31 | $1.24 | $1.29 | 1.58M |
| Sep 23, 2026 | $1.24 | $1.32 | $1.21 | $1.31 | 1.97M |
| Sep 22, 2026 | $1.13 | $1.25 | $1.12 | $1.23 | 1.67M |
| Sep 21, 2026 | $1.05 | $1.13 | $1.035 | $1.12 | 1.9M |
Latest ADCT news
The latest Smart Investors Daily articles mentioning ADCT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
ADCT research
Overview
Company profile and research snapshot.
Company profile
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $7.50
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 17, 2026 | Guggenheim | Buy | — |
| Jun 8, 2026 | HC Wainwright & Co. | Neutral | — |
| Jun 4, 2026 | RBC Capital | Sector Perform | — |
| May 5, 2026 | RBC Capital | Outperform | — |
| May 5, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Oct 9, 2026
ADC Therapeutics: Shares Spike On Restructuring, But Safety Fears Undermine Bull Thesis
ADC Therapeutics' restructuring extends cash runway to 2029, but Zynlonta safety/regulatory risks loom. Click here to read this analysis of ADCT stock.
Yahoo · Oct 8, 2026
ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a comprehensive strategic financial restructuring designed to strengthen its balance sheet, reduce leverage, and increase strategic optionality to maximize shareholder value while extending the expected cash runway into 2029. The strategic initiative includes securing new equity financing, restructuring the HealthCare Royalty (HCR) agreement, and reducin
Benzinga · Oct 8, 2026
ADC Therapeutics Announces $86.6M Pipe Financing For 12.9M Shares At $1.42/Share And Warrants To Purchase 48.1M Shares At $1.32/Warrant; Secures Loan And Royalty Amendments
ADC Therapeutics has entered into securities purchase agreements for the sale of its equity securities to certain institutional investors, including new investor Bain Capital Life Sciences and existing investors
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
